Online inquiry

IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15986MR)

This product GTTS-WQ15986MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Felcat IL31 gene. The antibody can be applied in Feline atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Felinized
RefSeq XM_011287838.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 105261056
UniProt ID A0A337S7E6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15986MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15106MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ10545MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ8447MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ13946MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ3858MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ14428MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ9941MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ15353MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW